UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part I: Early Screening for Potential Human Mutagens

Toxicological sciences, 2007-03, Vol.96 (1), p.16-20

2007

Volltextzugriff (PDF)

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints

Regulatory toxicology and pharmacology, 2006-03, Vol.44 (2), p.83-96

2006

Volltextzugriff (PDF)

A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software

Regulatory toxicology and pharmacology, 1998-12, Vol.28 (3), p.242-264

1998

Volltextzugriff (PDF)

Carcinogenicity Testing and the Evaluation of Regulatory Requirements for Pharmaceuticals

Regulatory toxicology and pharmacology, 1997-04, Vol.25 (2), p.130-145

1997

Volltextzugriff (PDF)

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods

Regulatory toxicology and pharmacology, 2006-03, Vol.44 (2), p.97-110

2006

Volltextzugriff (PDF)

Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices

Regulatory toxicology and pharmacology, 2003-12, Vol.38 (3), p.243-259

2003

Volltextzugriff (PDF)

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose

Regulatory toxicology and pharmacology, 2004-12, Vol.40 (3), p.185-206

2004

Volltextzugriff (PDF)

Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data

The Journal of pharmacology and experimental therapeutics, 1990-04, Vol.253 (1), p.104

1990

Volltextzugriff (PDF)

In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software

Regulatory toxicology and pharmacology, 2005-12, Vol.43 (3), p.313-323

2005

Volltextzugriff (PDF)

Use of toxicological information in drug design

Journal of molecular graphics & modelling, 2000-12, Vol.18 (6), p.605

2000

Volltextzugriff (PDF)

Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies

The Journal of pharmacology and experimental therapeutics, 1989-06, Vol.249 (3), p.928

1989

Volltextzugriff (PDF)

Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling

Toxicology and applied pharmacology, 2007-07, Vol.222 (1), p.1-16

2007

Volltextzugriff (PDF)

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities

Regulatory toxicology and pharmacology, 2009-06, Vol.54 (1), p.23-42

2009

Volltextzugriff (PDF)

A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics

Journal of the American College of Toxicology, 1995-02, Vol.14 (1), p.1-10

1995

Volltextzugriff (PDF)

Response to Monro and Mehta proposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans

Clinical pharmacology and therapeutics, 1996-03, Vol.59 (3), p.265-267

1996

Volltextzugriff (PDF)

Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities

Regulatory toxicology and pharmacology, 2009-06, Vol.54 (1), p.1-22

2009

Volltextzugriff (PDF)

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models

Regulatory toxicology and pharmacology, 2007-12, Vol.49 (3), p.172-182

2007

Volltextzugriff (PDF)

Emerging Trends in NonClinical Safety Assessment for Therapeutics

Toxicologic pathology, 1994-03, Vol.22 (2), p.89-94

Contrera, Joseph F.

1994

Volltextzugriff (PDF)

Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans: Part C: Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities

Regulatory toxicology and pharmacology, 2009-06, Vol.54 (1), p.43-65

2009

Volltextzugriff (PDF)

A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals

Regulatory toxicology and pharmacology, 2007-03, Vol.47 (2), p.136-155

2007

Volltextzugriff (PDF)

Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine

Toxicology and applied pharmacology, 1989-09, Vol.100 (2), p.227-233

1989

Volltextzugriff (PDF)

A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database

Regulatory toxicology and pharmacology, 2007-03, Vol.47 (2), p.115-135

2007

Volltextzugriff (PDF)

The duration of non-rodent toxicity studies for pharmaceuticals

Toxicological sciences, 1999-06, Vol.49 (2), p.143-155

1999

Volltextzugriff (PDF)

QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors

Current drug discovery technologies, 2005-06, Vol.2 (2), p.55-67

2005

Volltextzugriff (PDF)

An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. I. Evidence for a Confounding Nonresponder Phenotype

Toxicologic pathology, 1998-07, Vol.26 (4), p.532-540

1998

Volltextzugriff (PDF)

1 – 25 von 283

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(264)
Mit Volltextzugriff
(232)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(201)
EZB Electronic Journals Library
(145)
Ovid
(127)
IngentaConnect Journals
(122)
Elsevier ScienceDirect Journals Complete
(67)
Publisher website
(63)
IngentaConnect Journals
(50)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(42)
Wiley Online Library
(35)
Springer Journals
(22)
Wiley Online Library
(21)
Ebook Central Perpetual and DDA
(16)
eBooks on EBSCOhost
(16)
Oxford Journals Online Current
(15)
Oxford Journals 2020 Medicine
(12)
Sage Journals
(12)
JSTOR
(10)
SpringerLink Series
(10)
Nature
(9)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part I: Early Screening for Potential Human Mutagens

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints

A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software

Carcinogenicity Testing and the Evaluation of Regulatory Requirements for Pharmaceuticals

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods

Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose

Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data

In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software

Use of toxicological information in drug design

Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies

Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities

A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics

Response to Monro and Mehta proposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans

Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models

Emerging Trends in NonClinical Safety Assessment for Therapeutics

Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans: Part C: Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities

A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals

Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine

A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database

The duration of non-rodent toxicity studies for pharmaceuticals

QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors

An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. I. Evidence for a Confounding Nonresponder Phenotype

Suchergebnisse filtern